Tumor immune cell subsets were not different across groups when looking at percentages of total immune cells (Figure 6); however, percentages of CD4 and CD8 T cells were increased in Poly(I:C)+ OX40+ TIM-3-treated tumors when looking at total tumor cells (Figure 7M,O), with this treatment exhibiting 90% complete tumor regression (Figure 4). The gene discussed is TNFRSF4; the disease is neoplasm.